Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy.

Background: A new topical formulation of betamethasone valerate (BMV) with enhanced dermal penetration has been developed.

Objective: These studies were designed to evaluate: (1) the relative bioavailability of BMV foam, and (2) the safety and efficacy of BMV foam in the treatment of scalp psoriasis as compared to a lotion formulation of BMV and placebo.

Methods: Safety and efficacy were evaluated in a randomized, multicenter, double-blind, active-and placebo-controlled trial in adult patients with moderate to severe scalp psoriasis.